An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Abemaciclib (Primary) ; Lasofoxifene (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Acronyms ELAINE 2; ELAINEII
- Sponsors Sermonix Pharmaceuticals
Most Recent Events
- 13 Feb 2025 Status changed from active, no longer recruiting to completed.
- 16 Aug 2024 Planned End Date changed from 31 May 2024 to 31 Dec 2024.
- 16 Aug 2024 Planned primary completion date changed from 31 May 2024 to 31 Dec 2024.